Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia study of AVL 292 in volunteers

Next Previous
Search
Trial Profile

Phase Ia study of AVL 292 in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spebrutinib (Primary)
  • Indications Autoimmune disorders; B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
    • 24 Jun 2011 Results presented at the Federation of Clinical Immunology Societies (FOCIS) in June 2011.
    • 11 Jun 2011 Results presented at the 16th Congress of the European Haematology Association (EHA-2011).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top